Related Experiment Videos
Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia
Kaushik Sen1, Anoop Misra, Atul Kumar
1Department of Medicine, All India Institute of Medical Sciences, New Delhi 110 029, India.
Insights
Simvastatin, a cholesterol-lowering drug, may slow the progression of diabetic retinopathy (DR) in patients with diabetes and high cholesterol. This study suggests HMG-CoA Reductase Inhibitors could be beneficial for preventing microvascular complications.
Area of Science:
- Ophthalmology
- Endocrinology
- Pharmacology
Background:
- Diabetic retinopathy (DR) is a complication of diabetes, with hyperlipidemia emerging as a significant risk factor alongside hyperglycemia and hypertension.
- Previous trials with older lipid-lowering agents showed limited efficacy in DR management.
- HMG-CoA Reductase Inhibitors (statins) present a promising therapeutic avenue for DR, though clinical trials were lacking.
Purpose of the Study:
- To evaluate the efficacy of simvastatin, an HMG-CoA Reductase Inhibitor, compared to placebo in patients with diabetic retinopathy.
- To assess the impact of simvastatin on lipid profiles and visual acuity in patients with DR.
Main Methods:
- A double-blind, randomized, placebo-controlled trial involving 50 patients with Type 1 or Type 2 diabetes mellitus and DR.
- Participants had good glycemic control, hypercholesterolemia, and visual acuity of 6/24 or better.
- Patients received either 20 mg of simvastatin daily or a placebo for 180 days.
Main Results:
- Simvastatin significantly reduced total cholesterol and LDL-C (P < 0.001) and increased HDL-C (P < 0.001).
- While not statistically significant, visual acuity improved in 4 simvastatin patients versus none in placebo.
- Crucially, no patients on simvastatin experienced worsening visual acuity, unlike 7 placebo patients (P = 0.009).
- Fundus imaging revealed improvement in 1 simvastatin patient, contrasted with worsening in 7 placebo patients (P = 0.009).
Conclusions:
- HMG-CoA Reductase Inhibitor therapy with simvastatin appears to significantly retard the progression of retinopathy in diabetic patients with hypercholesterolemia.
- Further research is warranted to explore the potential of statins for primary prevention of DR and other microvascular complications.
Abstract:
Besides hyperglycemia and hypertension, a recently recognized risk factor for diabetic retinopathy (DR) appears to be hyperlipidemia. While studies using earlier generation lipid lowering agents in DR were disappointing, a randomized trial using HMG-CoA Reductase Inhibitors has strong rationale, though hitherto not attempted. The aim of the present study was to compare the HMG-CoA Reductase Inhibitor, simvastatin, with placebo in patients having DR in a double-blind randomized placebo-controlled trial. Fifty patients with diabetes mellitus (Type 1 and 2) with good glycemic control and hypercholesterolemia and having DR (non-clinically significant macular edema and visual acuity 6/24 or better) in either or both eyes were randomized to simvastatin 20-mg per day or placebo, and were followed up for 180 days. On simvastatin therapy, total cholesterol and low-density lipoprotein cholesterol (LDL-C) decreased (P < 0.001, respectively), and the level of high-density lipoprotein cholesterol (HDL-C) increased (P < 0.001). VA improved in four patients using simvastatin, (not statistically different from placebo group) and worsening of VA occurred in seven patients in the placebo group and none in the simvastatin group (P = 0.009). Fundus fluorescein angiography and color fundus photograph showed improvement in one patient in the simvastatin group, while seven patients showed worsening in the placebo group (P = 0.009). The observations of the current study suggest that the HMG-CoA Reductase Inhibitor simvastatin significantly retards the progression of retinopathy in diabetic patients with hypercholesterolemia. The potential of this class of drugs for the primary prevention of DR and other microvascular complications needs to be explored further.